邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

中国经典型多发性硬化患者β干扰素-1b治疗前后血清尿酸水平

徐雁,  刘彩燕,  张遥,  孔令燕,  冯逢,  金征宇,  崔丽英

downloadPDF
文章导航 > 协和医学杂志  > 2012 >  3(3): 282-286
徐雁, 刘彩燕, 张遥, 孔令燕, 冯逢, 金征宇, 崔丽英. 中国经典型多发性硬化患者β干扰素-1b治疗前后血清尿酸水平[J]. 协和医学杂志, 2012, 3(3): 282-286. doi: 10.3969/j.issn.1674-9081.2012.03.008
引用本文: 徐雁, 刘彩燕, 张遥, 孔令燕, 冯逢, 金征宇, 崔丽英. 中国经典型多发性硬化患者β干扰素-1b治疗前后血清尿酸水平[J]. 协和医学杂志, 2012, 3(3): 282-286. doi: 10.3969/j.issn.1674-9081.2012.03.008
shu
Yan XU, Cai-yan LIU, Yao ZHANG, Ling-yan KONG, Feng FENG, Zheng-yu JIN, Li-ying CUI. Serum Uric Acid Levels in Chinese Patients with Classic Multiple Sclerosis: Before and After Treatment with Interferon-beta 1b[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 282-286. doi: 10.3969/j.issn.1674-9081.2012.03.008
Citation: Yan XU, Cai-yan LIU, Yao ZHANG, Ling-yan KONG, Feng FENG, Zheng-yu JIN, Li-ying CUI. Serum Uric Acid Levels in Chinese Patients with Classic Multiple Sclerosis: Before and After Treatment with Interferon-beta 1b[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 282-286. doi: 10.3969/j.issn.1674-9081.2012.03.008
shu

中国经典型多发性硬化患者β干扰素-1b治疗前后血清尿酸水平

doi: 10.3969/j.issn.1674-9081.2012.03.008
  • 1.

    中国医学科学院 北京协和医学院 北京协和医院 神经科, 北京 100730

  • 2.

    中国医学科学院 北京协和医学院 北京协和医院 放射科, 北京 100730

详细信息
    通讯作者:

    崔丽英 电话:010-69156373, E-mail:pumchcly@yahoo.com.cn

  • 中图分类号: R741

Serum Uric Acid Levels in Chinese Patients with Classic Multiple Sclerosis: Before and After Treatment with Interferon-beta 1b

  • 1.

    Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要:   目的  探讨中国经典型多发性硬化(classical multiple sclerosis, CMS)患者β干扰素-1b治疗前后血清尿酸(uric acid, UA)水平的变化及其与复发率、扩展残疾状态评分(Expanded Disability Status Scale, EDSS)和颅内增强病灶(contrast-enhancing lesions, CELs)数目间的关系。  方法  12例CMS患者(10例女性, 2例男性, 年龄:24~54岁)被纳入至一项为期6个月的疗效观察研究。在疾病缓解期, 给予β干扰素-1b(250 μg, 皮下注射, 隔日1次)治疗。治疗前后评估患者EDSS评分、年复发次数、颅内CELs数目和血清UA水平。  结果  治疗后, 患者年复发次数(0.0比0.9, P=0.011)和颅内CELs数目(0.0比1.5, P=0.007)较治疗前明显减低; EDSS评分有降低趋势(2.0比2.8), 但差异无统计学意义(P=0.064);血清UA水平从222.2 μmol/L升高至234.9 μmol/L, 但差异亦无统计学意义(P=0.213)。进一步研究发现, 血清UA水平升高与颅内CELs数目减低显著相关(r=-0.716, P=0.009)。  结论  血清UA水平有可能成为评估CMS患者对β干扰素-1b治疗反应的一个监测指标。
    Abstract:   Objective  To investigate the changes of serum uric acid (UA) level and its relationship with relapse rate, Expanded Disability Status Scale (EDSS) score, and the number of contrast-enhancing lesions (CELs) in Chinese patients with classic multiple sclerosis (CMS) before and after interferon (IFN) -beta 1b treatment.  Methods  Twelve patients (10 women and 2 men, aged 24 to 54 years) with definite CMS were enrolled into a 6-month open-label observational treatment study. IFN-beta 1b (250 μg, qod) was injected subcutaneously during remission stage. EDSS, relapse rate, number of CELs, and serum UA levels were examined both at baseline and at the end of the study.  Results  After treatment, the median relapse rate (0.0 vs. 0.9, P=0.011) and median number of CELs (0.0 vs. 1.5, P=0.007) decreased significantly compared with those before treatment. The median EDSS score also decreased from 2.8 to 2.0, but the difference was not statistically significant (P=0.064). Serum UA level increased from 222.2 μmol/L to 239.4 μmol/L after treatment, although the difference was not statistically significant (P=0.213). However, there was significant correlation between the increase in UA level and the decrease in number of CELs (r=-0.716, P=0.009).  Conclusions  UA may serve as an easily detectable and economic marker for the blood-brain barrier function in CMS patients and for the responses to IFN-beta 1b treatment.
    • HTML全文

  • 图  1  血清尿酸水平升高与颅内增强病灶数目减少显著相关(r = -0. 716，P =0. 009)

    下载: 全尺寸图片 幻灯片

    表  1  β干扰素-1b对患者EDSS、年复发次数、颅内增强病灶数目及血清尿酸水平的影响

    时间 EDSS (中位数) 年复发次数(中位数) 颅内增强病灶数目(中位数) 尿酸(μmol/L，x ± s)
    治疗前(缓解期) 2.8 0.9 1.5 222. 2 ± 28. 9
    治疗后6个月 2.0 0.0 0.0 239. 4 ± 48. 7
    P值 0.064 0.011 0.007 0.213
    EDSS:扩展残疾状态评分
    下载: 导出CSV
    • 参考文献(37)
  • [1] Liu JS, Zhao ML, Brosnan CF, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions[J]. Am J Pathol, 2001, 158:2057-2066. doi:  10.1016/S0002-9440(10)64677-9
    [2] Tran EH, Hardin-Pouzet H, Verge G, et al. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis[J]. J Neuroimmunol, 1997, 74:121-129. doi:  10.1016/S0165-5728(96)00215-9
    [3] Mitrovic B, Ignarro LJ, Montestruques S, et al. Nitric oxide as a potential pathological mechanism in demyelination:its differential effects on primary glial cells in vitro[J]. Neuroscience, 1994, 61:575-585. doi:  10.1016/0306-4522(94)90435-9
    [4] Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid[J]. Arch Biochem Biophys, 2000, 376:333-337. doi:  10.1006/abbi.2000.1721
    [5] Scott GS, Spitsin SV, Kean RB, et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors[J]. Proc Natl Acad Sci U S A, 2002, 99:16303-16308. doi:  10.1073/pnas.212645999
    [6] Hooper DC, Spitsin K, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis[J]. Proc Natl Acad Sci U S A, 1998, 95:675-680. doi:  10.1073/pnas.95.2.675
    [7] Zamani A, Rezaei A, Khaeir F, et al. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients[J]. Clin Neurol Neurosurg, 2008, 110:642-643. doi:  10.1016/j.clineuro.2008.03.002
    [8] Sotgiu S, Pugliatti M, Sanna A, et al. Serum uric acid and multiple sclerosis[J]. Neurol Sci, 2002, 23:183-188. doi:  10.1007/s100720200059
    [9] Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric acid and multiple sclerosis[J]. Clin Neurol Neurosurg, 2006, 108:527-531. doi:  10.1016/j.clineuro.2005.08.004
    [10] Spitsin S, Hooper DC, Mikheeva T, et al. Uric acid levels in patients with multiple sclerosis:analysis in mono- and dizygotic twins[J]. Mult Scler, 2001, 7:165-166. doi:  10.1177/135245850100700305
    [11] Toncev G, Milicic B, Toncev S, et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction[J]. Eur J Neurol, 2002, 9:221-226. doi:  10.1046/j.1468-1331.2002.00384.x
    [12] Mostert JP, Ramsaransing SM, Heersema DJ, et al. Serum acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses[J]. J Neurol Sci, 2005, 231:41-44. doi:  10.1016/j.jns.2004.12.008
    [13] Kastenbauer S, Kieseier BC, Becker BF. No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis[J]. J Neurol, 2005, 252:611-612. doi:  10.1007/s00415-005-0697-z
    [14] Ramsaransing GSM, Heersema DJ, De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis[J]. Eur J Neurol, 2005, 12:514-518. doi:  10.1111/j.1468-1331.2005.01009.x
    [15] Drulovic J, Dujmovic I, Stojsavljevic N, et al. Uric acid levels in sera from patients with multiple sclerosis[J]. J Neurol, 2001, 248:121-126. doi:  10.1007/s004150170246
    [16] Karg E, Klivenyi P, Nemeth I, et al. Nonenzymatic antioxidants of blood in multiple sclerosis[J]. J Neurol, 1999, 246:533-539. doi:  10.1007/s004150050399
    [17] Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases[J]. Mult Scler, 2008, 14:188-196. doi:  10.1177/1352458507082143
    [18] Constantinescu C, Freitag P, Kappos L. Increase in serum levels of uric acid, endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis[J]. Mult Scler, 2000, 6:378-381. doi:  10.1177/135245850000600603
    [19] Guerrero AL, Martín-Polo J, Laherrán E, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment[J]. Eur J Neurol, 2008, 15:394-397. doi:  10.1111/j.1468-1331.2008.02087.x
    [20] Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis:2005 revisions to the "McDonald Criteria"[J]. Ann Neurol, 2005, 58:840-846. doi:  10.1002/ana.20703
    [21] Lövblad KO, Anzalone N, Dörfler A, et al. MR imaging in multiple sclerosis:review and recommendations for current practice[J]. AJNR Am J Neuroradiol, 2010, 31:983-989. doi:  10.3174/ajnr.A1906
    [22] Mowry EM, Beheshtian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures[J]. Neurology, 2009, 72:1760-1785. doi:  10.1212/WNL.0b013e3181a609f8
    [23] Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFN beta-1b on the evolution of enhancing lesions in secondary progressive MS[J]. Neurology, 2001, 57:2185-2190. doi:  10.1212/WNL.57.12.2185
    [24] Milanese C, Mantia LL, Palumbo R, et al. A post-marketing study on interferon-beta 1b and 1a treatment in relapsingremitting multiple sclerosis:different response in drop-outs and treated patients[J]. J Neurol Neurosurg Psychiatry, 2003, 74:1689-1692. doi:  10.1136/jnnp.74.12.1689
    [25] Barkhof F, Polman CH, Radue EW, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study:integrated 2-year results[J]. Arch Neurol, 2007, 64:1292-1298. doi:  10.1001/archneur.64.9.1292
    [26] Gaindh D, Jeffries N, Ohayon J, et al. The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis[J]. Expert Opin Biol Ther, 2008, 8:1823-1829. doi:  10.1517/14712590802510629
    [27] Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis[J]. Eur J Neurol, 2001, 8:141-148. doi:  10.1046/j.1468-1331.2001.00189.x
    [28] Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis[J]. Acta Neurol Scand, 2006, 113:283-287. http://europepmc.org/abstract/MED/16629762
    [29] Flechter S, Vardi J, Finkelstein Y, et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b:an open-label prospective 1 year study[J]. Isr Med Assoc J, 2007, 9:457-459. http://www.ncbi.nlm.nih.gov/pubmed/17642394
    [30] Lily O, McFadden E, Hensor E, et al. Disease-specific quality of life in multiple sclerosis:the effect of disease modifying treatment[J]. Mult Scler, 2006, 12:808-813. doi:  10.1177/1352458506070946
    [31] Trojano M, Paolicelli D, Zimatore GB, et al. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice:the experience at the MS Center of Bari, Italy[J]. Neurol Sci, 2005, 26:S179-S182. doi:  10.1007/s10072-005-0511-9
    [32] Trojano M, Liguori M, Paolicelli D, et al. Interferon beta in relapsing-remitting multiple sclerosis:an independent postmarketing study in southern Italy[J]. Mult Scler, 2003, 9:451-457. doi:  10.1191/1352458503ms948oa
    [33] Flechter S, Vardi J, Pollak L, et al. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients:an open-label 2-year follow-up[J]. J Neurol Sci, 2002, 197:51-55. doi:  10.1016/S0022-510X(02)00047-3
    [34] Grossman RI, Braffman BH, Brorson JR, et al. Multiple sclerosis:serial study of gadolinium-enhanced MR imaging[J]. Radiology, 1988, 169:117-122. doi:  10.1148/radiology.169.1.3420246
    [35] Jimenez J, Jy W, Mauro LM, et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes[J]. Mult Scler, 2005, 11:310-315. doi:  10.1191/1352458505ms1184oa
    [36] Minagar A, Long A, Ma T, et al. Interferon (IFN) -beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier[J]. Endothelium, 2003, 10:299-307. doi:  10.1080/10623320390272299
    [37] Trojano M, Defazio G, Avolio C, et al. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells[J]. J Neurovirol, 2000, 6(Suppl 2):S47-S51. http://www.ncbi.nlm.nih.gov/pubmed/10871785
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(1) / 表(1)
计量
  • 文章访问数:  154
  • HTML全文浏览量:  44
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-05-03
  • 刊出日期:  2012-07-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！